1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Mercury Laboratories Limited

Mercury Laboratories Limited

MERCURYLAB.BO
Mercury Laboratories LimitedIN flagBombay Stock Exchange
805.00
INR
+36.00
- -
966.00MMarket Cap
Mercury Laboratories Limited
MERCURYLAB.BO
(Bombay Stock Exchange)

Recent

price

805.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
345.41
343.26
395.98
400.23
432.23
462.67
477.24
571.68
482.7
627.78
629.66
625.84
634.4
Revenue per Share
26.85
27.61
32.69
22.53
16.78
23.63
26.9
44.48
29.68
46.49
47.12
26.21
39.31
Basic EPS, GAAP
8.14
16.19
-3.13
3.51
10.43
1.94
36.26
29.95
27.29
11.63
16.28
-41.99
- -
Free Cash Flow per Basic Share
1.74
1.74
1.81
1.81
1.81
1.81
1.81
3.5
2
3.5
3.5
3.5
- -
Dividend per Share
10.13
10.24
10.45
9.83
13.12
18.28
22.54
34.35
31.15
44.98
59.43
82.14
- -
Book Value per Share
128.38
151.18
181.73
202.61
218.89
240.78
266.11
306.76
335.42
379.9
423.44
446.19
- -
Tangible Book Value per Share
1
1
1
1
1
1
1
1
1
1
1
1
1
Basic Weighted Avg Shares
414
412
475
480
519
555
573
686
579
753
756
751
762
Sales/Revenue/Turnover
13.77
13.39
11.13
11.99
5.67
7.38
7.79
13.44
8.25
8.76
10.14
9.87
11.94
Operating Margin (%)
9
12
12
13
15
16
19
19
25
25
28
29
33
Depreciation Expense
32
33
39
27
20
28
32
53
36
56
57
31
47
Net Income, GAAP
32.79
28.05
20.53
44.77
18.02
29.98
25.43
32.51
29.25
25.06
18.3
32.54
25.66
Effective Tax Rate (%)
7.77
8.04
8.26
5.63
3.88
5.11
5.64
7.78
6.15
7.41
7.48
4.19
6.2
Profit Margin (%)
13
22
111
150
167
150
164
190
195
253
272
251
- -
Working Capital
39
19
66
74
97
85
63
62
29
25
29
38
- -
LT Debt
154
181
218
245
263
290
320
369
403
456
508
536
- -
Total Equity
- -
16.81
13.48
8.37
6.43
7.38
8.24
14.4
7.17
10.12
12.01
9.02
- -
Return on Invested Capital (%)
- -
48.23
61.3
34.26
24.05
28.74
32.48
52.18
35.16
53.65
47.72
23.51
99.78
Return on Capital (%)
- -
271.2
316.03
222.13
146.24
150.58
131.83
156.39
90.63
122.14
90.26
37.03
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
13
- -
LT Borrowings
- -
40
- -
LT Finance Leases
- -
7
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1
- -
Market Capitalization
1,012
990
974

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
410
- -
Cash, Cash Equivalents & STI
- -
31
- -
Accounts Receivable, Net
- -
250
- -
Inventories
- -
72
- -
Total Current Liabilities
- -
120
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.51%
10.92%
5.37%
Free Cash Flow
115.5%
-80.33%
-357.95%
Net Income, GAAP
6.21%
9.13%
-44.38%
Sales/Revenue/Turnover
6.86%
6.8%
-0.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
183
228
171
174
756
2025
167
182
196
207
751
2026
181
190
184
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8.33
12.56
10.3
- -
47.12
2025
2.85
4.17
9.94
- -
26.21
2026
8.06
13.69
8.31
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.5
2025
- -
- -
- -
- -
3.5
2026
- -
- -
- -
- -
- -
Similar Companies
Shanghai No.1 Pharmacy Co., Ltd. (600833.SS)
TMT (India) Ltd. (TMTIND-B1.BO)
Fire & Flower Holdings Corp. (FAF.TO)
Noveris Health Sciences Inc. (MYCOF)
Cellular Goods PLC (CBX.L)
Tsuruha Holdings Inc. (3391.T)
Business
Mercury Laboratories Limited (MERCURYLAB.BO), founded in 1962 and headquartered in Vadodara, Gujarat, India, manufactures, markets, exports and distributes pharmaceutical formulations primarily focused on mother and child healthcare, gynecology and pediatrics segments; its core products encompass tablets, oral liquids, small volume parenterals, ophthalmic and ear drops across therapy areas including analgesics, anti-inflammatories, anti-pyretics, anthelmintics, antibiotics, anti-coagulants, anti-platelets, haemostats, anti-fungals, anti-hypertensives, anti-malarials, cardiovascular, central nervous system, gastro-intestinal, hypoglycemics, multivitamins, protein supplements, respiratory, anti-allergics, steroids, urinary tract and uterine stimulants; the company operates state-of-the-art facilities spanning 435,600 square feet with separate units for tablets, liquids, injectables and ophthalmics, holding international accreditations such as WHO-GMP, NAFDAC Nigeria, FDA Ghana, DPML Ivory Coast, MoH Congo, CDDA Sri Lanka and MoH Cambodia, serving domestic and global markets in Africa, Asia and beyond. In recent developments, Mercury Laboratories reported standalone net profit surging 228% to Rs 1.64 crore for the quarter ended September 2025, with sales up 4.51% year-over-year to Rs 19.01 crore, alongside March 2025 net sales growth of 18.95% to Rs 20.66 crore, reflecting improved operational performance amid stable promoter holding of 73.66% and minimal debt.